Showing results (1-10 of 113) with videos related to

Sort By:
Pageof 12
Journal of Atrial Fibrillation|December 3, 2016
Symptom/Rhythm Correlation With Patient Owned Device: Insights Into Practice And ChallengesMohammed Shurrab, Anatoly Langer, Eugene Crystal, et al.
The Canadian Journal of Cardiology|May 27, 2005
Enoxaparin and percutaneous coronary intervention: a Canadian perspectiveDavid Fitchett, Robert Welsh, Anatoly Langer, et al.
The Canadian Journal of Cardiology|September 13, 2008
Ischemic stroke: a cardiovascular risk equivalent? Lessons learned from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trialDavid H Fitchett, Shaun G Goodman, Anatoly Langer
Experimental and Clinical Cardiology|April 4, 2009
Recommendations for management of dyslipidemia in high cardiovascular risk patientsManoela B Braga, Anatoly Langer, Lawrence A Leiter
The Canadian Journal of Cardiology|December 5, 2002
Preventing thrombosis: update of first-line therapy in the management of non-ST segment elevation acute coronary syndromesDavid Fitchett, Shaun G Goodman, Milan Gupta, et al.
The Canadian Journal of Cardiology|September 8, 2006
Lower is better: implications of the Treating to New Targets (TNT) study for Canadian patientsDavid H Fitchett, Lawrence A Leiter, Shaun G Goodman, et al.
Circulation|January 23, 2003
Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatideShaun G Goodman, David Fitchett, Paul W Armstrong, et al.
The Canadian Journal of Clinical Pharmacology = Journal Canadien De Pharmacologie Clinique|August 11, 2004
A pharmacoeconomic evaluation of the myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) study in CanadaRoman Casciano, Jean-Eric Tarride, Marie Claude Breton, et al.
The Canadian Journal of Cardiology|February 3, 2005
Are Canadian guidelines for cholesterol lowering in high-risk patients optimal?David H Fitchett, Lawrence A Leiter, Jean-Claude Tardif, et al.
Atherosclerosis|December 4, 2003
Skin tissue cholesterol (SkinTc) is related to angiographically-defined cardiovascular diseaseDennis L Sprecher, Shaun G Goodman, Paul Kannampuzha, et al.
Pageof 12